https://www.selleckchem.com/pr....oducts/golidocitinib
Services also differed in how they evaluated the quality of CST and how this evidence was incorporated for future sessions.Conclusion While there was a low response rate, this survey indicates that there is significant variability in how CST is used in clinical practice, with many trusts not adhering to the evidence base. To ensure that people with dementia are consistently offered evidence-based, high-quality CST across NHS settings, further standardisation of inclusion criteria, dose and outcomes is needed
Like
Comment
Share
